Determining reference ranges for lymphocyte proliferation responses to phytohemagglutinin and Bacillus Calmette-Guérin in Iranian children

Copyright © 2024. Published by Elsevier Inc.

Détails bibliographiques
Publié dans:Clinical immunology (Orlando, Fla.). - 1999. - 261(2024) vom: 30. Apr., Seite 109937
Auteur principal: Nourizadeh, Maryam (Auteur)
Autres auteurs: Sarrafzadeh, Shokouh Azam, Shoormasti, Raheleh Shokouhi, Fazlollahi, Mohammad Reza, Saghafi, Shiva, Badalzadeh, Mohsen, Mirmoghtadaei, Milad, Pourpak, Zahra
Format: Article en ligne
Langue:English
Publié: 2024
Accès à la collection:Clinical immunology (Orlando, Fla.)
Sujets:Journal Article Research Support, Non-U.S. Gov't Bacillus Calmette–Guérin Cellular proliferation Lymphocyte stimulation Mendelian susceptibility to mycobacterial disease Phytohemagglutinin Reference ranges Severe combined immunodeficiency Phytohemagglutinins BCG Vaccine
Description
Résumé:Copyright © 2024. Published by Elsevier Inc.
PURPOSE: To establish reference ranges (RRs) for stimulation index of T cell proliferation triggered by phytohemagglutinin (PHA-SI) and Bacillus Calmette-Guérin (BCG-SI)
METHODS: This study investigated data from 359 healthy children and 35 patients with cellular immunodeficiency as positive controls (2010-2021). We applied a colorimetric-based method (BrdU) to measure proliferation and determine the RRs at the 2.5th and 97.5th percentiles (95% confidence intervals). A cross-validation approach was performed
RESULTS: In healthy controls, the RRs for PHA-SI and BCG-SI ranged between 3 and 5.2 and 2.52 to 5.2, respectively. PHA-SI and BCG-SI were in Severe Combined Immunodeficiency (SCID) patients from 1.2 to 2.5 and 0 to 2, while in Mendelian susceptibility to mycobacterial diseases (MSMD) patients, 2.53 to 4.5 and 0.74 to 2.2, respectively. The thresholds' accuracy was checked for testing reference intervals with diagnostic effects
CONCLUSION: This study establishes PHA-SI and BCG-SI reference ranges to aid in diagnosing and treating congenital immunodeficiency diseases
Description:Date Completed 18.03.2024
Date Revised 10.04.2024
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2024.109937